In patients with diabetes mellitus, contradictory results have been reporte
d indicating both increased and reduced risks of malignancies. In the prese
nt trial all insulin-treated diabetic patients (n = 2720) attending our cen
tre since 1995 were studied. Of these patients, 28 (type 1/type 2. n = 1/27
, 23 women) developed malignancies during insulin therapy: 11 patients deve
loped cancer of the breast. 4 patients cancer of the pancreas, 3 patients c
ancer of the kidneys and 10 patients developed other malignancies. The char
acteristics of these patients [mean +/- SD (range)] were as follows: age 68
.8 +/- 8.6 (52.0-87.0) years, diabetes duration 13.1 +/- 8.1 (0.5-29.0) yea
rs, duration of insulin therapy at the time of the diagnosis of malignancy
4.3 +/- 5.7 (0.5-24.0) years, insulin dosage 0.67 +/- 0.43 (0.11-1.72) IU/k
g body weight, mean HbAlc 9.6 +/- 1.9 (6.8-14.9)% (HPLC, Diamat, normal ran
ge 4.4%-5.9%). The prevalences of nephropathy, retinopathy (non-proliferati
ve: n = 7) and peripheral neuropathy were 35.7%, 25.0% and 46.4% respective
ly. When the features of the 27 patients with type 2 diabetes were compared
with the characteristics of the type 2 diabetic patients (n = 117, 63 wome
n) studied in a population-based survey of insulin-treated diabetic patient
s, also performed in the area of Jena [JEVIN; Schiel R et al. (1997a)] ther
e were no significant differences in the duration of insulin therapy (JEVIN
: 4.7 +/- 4.3 years, P = 0.64), insulin dosage (JEVIN: 0.55 +/- 0.27 IU/kg
body weight, P = 0.08), mean HbAlc (JEVIN: 9.0 +/- 2.1%, P = 0.16) and the
prevalences of long-term complications of diabetes. The quality of diabetes
control in insulin-treated patients suffering from malignancies is compara
ble to that of a selection-free population of diabetic patients. Furthermor
e, in comparison to non-diabetic subjects our diabetic patients showed no a
ltered risk for malignancies as a function of insulin dosage, the duration
of diabetes or insulin therapy, the quality of diabetes control or the prev
alence of long-term complications of the disease.